Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
Open Access
- 1 October 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (10) , 1249-1254
- https://doi.org/10.1023/a:1008351310818
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Taxanes in the Treatment of Breast Cancer: A Prodigy Comes of AgeCancer Investigation, 1999
- A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.Journal of Clinical Oncology, 1998
- Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancerAnnals of Oncology, 1997
- First-line treatment of metastatic breast cancerAnti-Cancer Drugs, 1996
- Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.Journal of Clinical Oncology, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Docetaxel.Journal of Clinical Oncology, 1995
- Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicityCancer Treatment Reviews, 1993
- Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1992
- 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical dataCancer Treatment Reviews, 1983